Searchable abstracts of presentations at key conferences on calcified tissues

ISSN 2052-1219 (online)

Bone Abstracts

Published by BioScientifica

Previous issue | Volume 3 | ECTS2014 | Next issue

European Calcified Tissue Society Congress 2014

Prague, Czech Republic
17 May 2014 - 20 May 2014

Card image cap

European Calcified Tissue Society Annual Congress, 17 - 20 May 2014; Prague, Czech Republic

Oral Posters

Clinical

Table of contents

Next section
Pre-Clinical

A transdermal patch delivering the PTHrP1-34 analog, abaloparatide (BA058), dose-dependently increases spine and hip bmd compared to placebo

Yates John Alexandersen Peter Krogsaa Annesofie Nedergaard Bettina Clarkin Marcie Hattersley Gary Hansen Kris Karsdal Morten Christiansen Claus

ba0003OP1

Abaloparatide (BA058), a novel human PTHrP analog, restores bone mass and strength in the aged osteopenic ovariectomized cynomolgus monkey

Hattersley Gary Doyle Nancy Varela Aurore Guldberg Robert E Smith Susan Y

ba0003OP2

PTH treatment induces WNT10b expression in humans lymphoid cells

D'Amelio Patrizia Sassi Francesca Buondonno Ilaria Spertino Elena D'Amico Lucia Roato Ilaria Isaia Giovanni Carlo

ba0003OP3

Denosumab treatment in women with osteoporosis reduces hip cortical porosity

Zebaze Roger M Libanati Cesar McClung Michael R Zanchetta Jose R Kendler David L Hoiseth Arne Wang Andrea Ghasem-Zadeh Ali Seeman Ego

ba0003OP4

Continuous modelling-based bone formation could explain sustained increases in hip bone mineral density with denosumab treatment

Ominsky Michael S Libanati Cesar Boyce Rogely Kostenuik Paul J Baron Roland Wagman Rachel B Dempster David W

ba0003OP5

Changes in lumbar spine QCT, DXA and TBS with denosumab, alendronate or placebo in postmenopausal women with low bone mass

Thomas Thierry Cheung Angela M Shane Elizabeth Zanchetta Jose R Kearns Ann Hans Didier Lin Celia J F Austin Matthew Libanati Cesar

ba0003OP6

In postmenopausal women previously treated with an oral bisphosphonate and at higher risk of fracture, denosumab significantly increases bone mineral density compared with ibandronate and risedronate

Brown Jacques P Bolognese Michael A Ho Pei-Ran Roux Christian Bone Henry G Bonnick Sydney L van den Bergh Joop Ferreira Irene Ghelani Prayashi Dakin Paula Wagman Rachel B Recknor Christopher

ba0003OP7

Effects of up to 15 years of recombinant human GH replacement therapy on the skeleton in adult GH deficiency: the Leiden Cohort Study

Appelman-Dijkstra Natasha Claessen Kim Hamdy Neveen Pereira Alberto Biermasz Nienke

ba0003OP8

Zoledronate prevents lactation induced loss of bone strength and micro-architecture

Wendelboe Mette Hoegh Thomsen Jesper Skovhus Bruel Annemarie

ba0003OP9

Zoledronate reverses bone marrow adiposity in disuse osteopenic rats

Jensen Michael Vinkel Bruel Annemarie Thomsen Jesper Skovhus

ba0003OP10

A randomized, double-blind, placebo-controlled, ascending, single-dose study of a human monoclonal anti-FGF23 antibody (KRN23) in X-linked hypophosphatemia

Carpenter Thomas Imel Erik Ruppe Mary Weber Thomas Klausner Mark Wooddell Margaret Kawakami Tetsuyoshi Ito Takahiro Zhang Xiaoping Humphrey Jeffrey Insogna Karl Peacock Munro

ba0003OP11

Pharmacokinetics and pharmacodynamics of a human monoclonal anti-FGF23 antibody (KRN23) after ascending single-dose administration in patients with X-linked hypophosphatemia

Zhang Xiaoping Carpenter Thomas Imel Erik Ruppe Mary Weber Thomas Klausner Mark Kawakami Tetsuyoshi Ito Takahiro Humphrey Jeffrey Insogna Karl Peacock Munro

ba0003OP12

Decrease in expression of MMP3 in osteoblast protects against bone loss

Zarka-Prost-Dumont Mylene Jehan Frederic Ostertag Agnes de Vernejoul Marie-Christine Geoffroy Valerie

ba0003OP13

Ten year alendronate use does not adversely affect bone quality compared to 5 years use: a human iliac crest biopsy study

Hassler Norbert Gamsjaeger Sonja Hofstetter Birgit Brozek Wolfgang Misof Barbara Roschger Paul Klaushofer Klaus Paschalis Eleftherios

ba0003OP14

Predictors of second fracture while on treatment with oral bisphosphonates: a multinational retrospective cohort study

Hawley Sam Wallace Gemma Javaid M Kassim Rubin Katrine Judge Andrew Vestergaard Peter Eastell Richard Diez-Perez Adolfo Arden Nigel K Cooper Cyrus Prieto-Alhambra Daniel Abrahamsen Bo

ba0003OP15

The impact of common comorbidities (as measured using the Charlson index) on hip fracture risk in elderly men: a population-based cohort study

Reyes Carlen Nogues Xavier Cooper Cyrus Diez-Perez Adolfo Prieto-Alhambra Daniel

ba0003OP16

Dynamic changes in bone marrow adiposity during the menstrual cycle

Veldhuis-Vlug Annegreet Limonard Eelkje van Dussen Laura Runge Jurgen Tanck Michael Endert Erik Heijboer Annemieke Fliers Eric Hollak Carla Akkerman Erik Bisschop Peter

ba0003OP17

Does bone density, bone strength, sarcopenia or dynapenia explain greater risk of fracture in obesity?

Evans Amy Eastell Richard Walsh Jennifer

ba0003OP18

Effect of subcutaneous recombinant human parathyroid hormone, rhPTH(1--84), on skeletal dynamics in hypoparathyroidism: findings from the 24-week replace and 8-week relay phase III clinical trials

Bilezikian John P Maruani Gerard Rothman Jeffrey Clarke Bart L Mannstadt Michael Vokes Tamara Lagast Hjalmar Shoback Dolores M

ba0003OP19

No beneficial effects of vitamin D supplementation in muscle function or quality of life in primary hyperparathyroidism: results from a randomized controlled trial.

Rolighed Lars Rejnmark Lars Sikjaer Tanja Heickendorff Lene Vestergaard Peter Mosekilde Leif Christiansen Peer

ba0003OP20

Bone Abstracts
ISSN 2052-1219 (online)
© Bioscientifica 2021 | Privacy policy | Cookie settings

Biosci Abstracts Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.

Find out more